TP53 and urinary bladder carcinoma: Noting that 60–70% of bladder carcinomas have p53 amounts, the authors remark that cells containing a p53 WT pass through a G1 checkpoint after exposure to topoisomerase II (etposide) inhibitors, cell cycle phase transition that allows them to repair DNA-induced lesions.